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IntroductIon
EBV, an endemic herpesvirus, infects more than 90% of the 
human population worldwide. Usually contracted during 
early childhood, EBV is subsequently carried for life as an 
asymptomatic latent infection. However, if the primary in-
fection is delayed, it can give rise to infectious mononucle-
osis (IM), a transient but often debilitating condition. More 
severe are the malignant diseases caused by EBV, the first 
human tumor virus identified (Epstein et al., 1964). These 
cancers include Burkitt lymphoma (BL), Hodgkin disease, 
and lymphomas associated with AIDS or transplantation 
(Young and Rickinson, 2004).
Main targets for EBV infection are epithelial cells and 
B lymphocytes. In vivo, EBV infection of B cells is controlled 
by the human host’s immune system. Consequently, only 
some EBV-infected cells survive to become long-lived mem-
ory B cells. In these cells, viral gene expression is turned off, 
giving a form of latent infection termed “latency 0.” When 
EBV-infected memory B cells divide, the Epstein–Barr nu-
clear antigen 1 (EBNA1) protein is expressed. It links viral 
episomes to host chromosomes, enabling the viral genome to 
be replicated along with that of the human host. This form 
of latent infection, termed “latency I,” also characterizes BL 
(Hochberg et al., 2004).
Induction of the lytic cycle in latently infected B cells 
requires expression of the viral immediate-early protein 
BZLF1 (Countryman et al., 1987). Although the physiologi-
cal stimuli that trigger in vivo reactivation of EBV are poorly 
understood, reactivation of EBV in some BL cell lines can be 
achieved in vitro by cross-linking the BCR with anti-BCR 
antibodies (Takada et al., 1991).
In the infected human host, EBV induces a diverse cel-
lular immune response. CD8 T cells, specific for lytic and la-
tent viral antigens, are prominent in controlling EBV in vivo 
(Hislop et al., 2007). In establishing latent infection, EBV uses 
various mechanisms to prevent T cell recognition of infected 
cells. During the lytic cycle, EBV impedes expression of HLA 
class I and II (Keating et al., 2002), as well as translocation of 
viral peptides to the endoplasmic reticulum by transporter 
associated with antigen processing (TAP; Ressing et al., 2005). 
Studying mice with a humanized immune system (Chijioke 
et al., 2013) showed how NK cells can control primary EBV 
infection, by limiting viral load and preventing progression to 
EBV-induced malignancy. That the peripheral blood of IM 
patients contains abnormally high numbers of NK cells (Wil-
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liams et al., 2005; Azzi et al., 2014) points to a crucial role for 
NK cells in the immune response to EBV.
Several studies on genetic disorders affecting T cells, 
NK cells, invariant NKT (iNKT) cells, or innate lymphoid 
cells have explored the potential protective effect of these 
immune compartments on viral infections including EBV 
(Sayos et al., 1998; van Montfrans et al., 2012; Li et al., 2014; 
Vély et al., 2016). However, an outstanding question is how 
the innate immune response to EBV differs between symp-
tomatic and asymptomatic primary infections among healthy 
humans. In response to EBV, a preferential expansion of NK-
G2A+KIR− NK cells has been observed (Azzi et al., 2014; 
Hatton et al., 2016), but the phenotypic and functional di-
versity of these and other responding innate lymphocytes 
has yet to be explored in detail. To address this question, we 
studied the response of NK cells, γδ T cells, and other innate 
immune cells to BL cells.
rEsuLts
nK cells and Vγ9Vδ2 t cells proliferate in response to 
latently infected EBV+ B cells
Down-regulation of host HLA class I is a strategy EBV 
uses to evade virus-specific cytotoxic T cells (Ressing et al., 
2005). A possible side effect of this ploy is that EBV-infected 
cells become more vulnerable to attack by NK cells, which 
actively respond to loss of autologous HLA class I. To ex-
plore this possibility, we studied the NK cell response to 
Akata, a BL cell line that is latently infected with EBV but 
can be induced to enter the lytic cycle by cross-linking its 
BCR with IgG-specific antibody. For the negative control, 
we used a derivative of Akata that is EBV−. The efficiency 
of EBV reactivation was determined by intracellular staining 
for the EBV protein BZLF1.
The response of human PBMCs to EBV− and EBV+ 
Akata cells, either preincubated or not with anti-IgG, was 
compared. To avoid bias caused by HLA class I or killer cell 
immunoglobulin-like receptor (KIR) ligand mismatch, we 
studied NK cells from three donors who shared the Bw4 
and C1 epitopes with Akata, as well as individual HLA-A, -B, 
and -C allotypes (Table 1). With this experimental design, we 
could determine which cellular responses are specific to EBV 
and how latent and lytic EBV infections affect the response. 
From the results of a previous study (Williams et al., 2016), 
we expected that NK cell responses to lytic infection would 
be greater than those to latent infection.
Five million PBMCs from each donor were cultured 
with the two subclones of Akata, either preincubated or not 
with anti-IgG. After 10 d of culture, flow cytometry was 
used to assess the proliferation of B cells (CD20+), NK cells 
(CD20−CD3−CD56+), αβ T cells (CD3+γδTCR−), and γδ 
T cells (CD3+γδTCR+). Akata cells were killed in all cul-
tures. NK cell proliferation was higher in cultures with latent 
EBV+ Akata cells than in cultures with EBV− Akata, whether 
preincubated or not with anti-IgG (P < 0.001), or in those 
with lytic EBV+ Akata (P < 0.001). Similar expansions of NK 
cells were seen for each donor, and the results were reproduc-
ible in three independent experiments. In all cultures with 
latent EBV+ Akata cells, the NK cell number rose by >60 
fold, resulting in ∼30 million cells, accounting for ∼40% of 
all cells (Fig. 1, A and B).
Vigorous γδ T cell responses to latent EBV+ Akata were 
observed for donors 2 and 3, but not for donor 1. The pro-
liferating γδ T cells express the Vγ9Vδ2 receptor. In PBMCs, 
Vγ9Vδ2 T cells typically constitute <5% of CD3+ T cells. 
After 10 d of culture with latent EBV+ Akata, the number of 
Vγ9Vδ2 T cells increased >500-fold, giving >20 million cells, 
comprising >20% of all cells (Fig. 1, A and B). This impressive 
proliferation of Vγ9Vδ2 T cells in response to latent EBV+ 
Akata cells was both unexpected and never observed for the 
Vγ9Vδ2 T cells of donor 1. Nor was it observed in cultures 
with EBV− Akata or lytic EBV+ Akata. For each donor, re-
producible results were obtained in three independent ex-
periments. Inversely correlating with the proportions of NK 
cells and Vγ9Vδ2 T cells, the proportion of αβ T cells was 
high in all cell cultures, except for those with latent EBV+ 
Akata (Fig. 1, A and B).
In conclusion, these results implicate NK cells and 
Vγ9Vδ2 T cells as major players in the innate immune de-
fense against EBV. Moreover, latent EBV infection stim-
ulates greater proliferation of NK cells and Vγ9Vδ2 T cells 
than lytic EBV infection.
Amplified Vγ9Vδ2 t cells activated by EBV 
express a high level of HLA-dr
Because antigen-activated T cells and NK cells are known to 
up-regulate HLA-DR expression (Salgado et al., 2002; Evans 
et al., 2011), we determined whether the NK and Vγ9Vδ2 T 
cells that respond to Akata also up-regulate HLA-DR. For 
proliferating populations of NK cells, CD4 T cells, CD8 T 
cells, and Vγ9Vδ2 T cells, cell-surface HLA-DR was much 
increased on day 10 compared with day 0. The Vγ9Vδ2 T 
cells achieved significantly higher HLA-DR expression than 
other lymphocyte populations (Fig. 1 C), indicating that these 
Vγ9Vδ2 T cells are highly activated. Combining these data 
Table 1. HLA-A, -B, and -c genotypes of the Akata cell line and donors 1, 2, and 3
name HLA-A A Bw4 HLA-B B Bw4 HLA-c c1/c2
Akata A*24 A*31 + − B*35 B*51 + + C*03 C*14 C1 C1
Donor 1 A*24 A*02 + − B*35 B*51 + + C*03 C*15 C1 C2
Donor 2 A*24 A*02 + − B*52 B*51 + + C*12 C*14 C1 C1
Donor 3 A*24 A*24 + + B*52 B*51 + + C*12 C*14 C1 C1
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with additional flow cytometric analysis showed that activated 
Vγ9Vδ2 T cells have a surface phenotype that is CD3+H-
LA-DR+CD56+/− and CD4−CD8−CD16−CD19−CD21−. 
Oyoshi et al. (2003) described Vγ9Vδ2 T cell lines of similar 
phenotype, which they established from PBMCs of patients 
with chronic active EBV infection. That these lines were 
EBV infected suggested that our Akata-activated Vγ9Vδ2 T 
cells could be similarly infected. To assess this possibility, the 
EBV-activated Vγ9Vδ2 T cells were assayed for presence of 
viral DNA encoding EBNA1. Whereas EBNA1 encoding 
DNA was successfully amplified from EBV+ Akata, it was not 
detected in any Vγ9Vδ2 T lymphocyte population or EBV− 
Akata (unpublished data). Thus, the in vitro–derived Vγ9Vδ2 
T cell lines obtained in our experiments are not infected with 
EBV and therefore differ from those derived from patients 
with chronic active EBV infection.
To define in detail the surface phenotypes of the 
NK cells and Vγ9Vδ2 T cells that respond to EBV+ 
Akata, we performed mass cytometric analysis of unstim-
ulated (day 0) and stimulated (day 10) cells, using a panel 
of 31 mAbs that target hematopoietic cell lineage markers 
and a variety of NK cell receptors (Table S1). The gating 
used to identify and distinguish NK cells and Vγ9Vδ2 T 
cells is shown in Fig. S1.
Figure 1. nK cells and Vγ9Vδ2 t cells proliferate in response to latently infected EBV+ B cells. PBMCs were stimulated in culture for 10 d with IL2 
and target cells. The targets were either EBV+ (denoted EBV +) or EBV− (denoted EBV −) Akata. They were either stimulated with anti-IgG (denoted IgG +) or 
not stimulated (denoted IgG −). (A) For day 10 cultures, histograms show the percentage of total cell number that were NK cells, Vγ9Vδ2 T cells, and αβ T 
cells. Shown are the results from one experiment, representing three performed. (B) Histograms show the absolute numbers of NK cells and Vγ9Vδ2 T cells 
in day 10 cultures. Shown are the results from one experiment, representing three performed. (C) Histogram comparing the mean fluorescence intensity 
(MFI ± SD; n = 4) for HLA-DR expression by NK cells, Vγ9Vδ2 T cells, CD4 T cells, and CD8 T cells at day 0 (gray bars) and day 10 (black bars) of PBMC stim-
ulation with latent EBV+ Akata and IL2. Shown are the results from one experiment, representing four performed, two on donor 2 PBMCs and two on donor 
3 PBMCs. Statistical significance in the difference between pairs of cell types was tested using ANO VA. Statistically significant differences (***, P < 0.0001) 
were observed between Vγ9Vδ2 T cells and each of the other three cell types.
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EBV-stimulated nK cells exhibit a phenotype of early 
differentiation that is independent of cMV status
IM patients have an expanded population of CD56dim NK 
cells that express CD94 :NKG2A, the inhibitory HLA-E 
receptor, and lack self-reactive KIR (Azzi et al., 2014). On 
the other hand, individuals infected with CMV, another 
common endemic herpesvirus, have an expanded population 
of NK cells that coexpress CD94 :NKG2C, the activating 
HLA-E receptor, and inhibitory KIR that recognize self 
HLA class I (Béziat et al., 2012; Foley et al., 2012; Djaoud 
et al., 2013). To see whether CMV infection influences the 
NK cell response to EBV, we compared the expression of 
NKG2A and C1-specific KIR2DL2/3 on Akata-activated 
NK cells from three donors: CMV+ donor 3 and CMV− 
donors 1 and 2 (Fig. 2 A).
For all three donors, the major population of proliferat-
ing NK cells was the KIR−NKG2C−NKG2A+ cells. During 
the 10 d of culture with EBV, KIR−NKG2C−NKG2A+ 
NK cells increased their representation in the total NK cell 
population from 45 to 85% for donor 1, from 35 to 83% 
for donor 2, and from 25 to 80% for donor 3. Consistent 
with previous observations (Béziat et al., 2012; Foley et al., 
2012; Djaoud et al., 2013), donor 3 had an expanded pop-
ulation of KIR+NKG2C+NKG2A− NK cells, the conse-
quence of CMV infection, which was not present in donors 
1 and 2. On day 0, KIR+NKG2C+NKG2A− NK cells were 
10% of donor 3’s NK cells, and this increased to 13% on 
day 10. Challenge with EBV was thus seen to stimulate a 
modest activation and proliferation of donor 3’s KIR+ 
NKG2C+NKG2A− NK cells. Although their representation 
increased by 3%, that of the KIR−NKG2C−NKG2A+NK 
cells increased by 55% (Fig. 2 A).
From this comparison of one CMV+ and two CMV− 
donors, we conclude that expansion of NKG2C+KIR+NK 
cells in response to CMV has no appreciable effect on a sub-
sequent KIR−NKG2C−NKG2A+NK cell response to EBV.
EBV-stimulated nK cells and Vγ9Vδ2 t cells 
exhibit similar phenotypes
Surface expression of CD94 :NKG2A and other NK cell 
receptors by NK cells and Vγ9Vδ2 T cells from donors 2 
and 3 (Table S1) was visualized using a 2D representation 
that provides resolution at the single-cell level. To do this, we 
constructed a visual stochastic network embedding (viSNE) 
map (Amir et al., 2013) for each receptor (Fig.  2 B). After 
a 10-d stimulation with EBV, the dominant subsets of NK 
cells and Vγ9Vδ2 T cells expressed high surface levels of 
inhibitory CD94 :NKG2A and activating NKG2D, DNAM-
1, and 2B4. In addition to these receptors, NK cells expressed 
a high level of the activating receptor NKp30. Almost all the 
cells were CD2bright and lacked the CD16 and CD57 markers 
of NK cell maturation (not depicted). Moreover, Siglec-7 
expression of Akata-stimulated NK cells was decreased from 
that of unstimulated NK cells, but they showed no change 
in KIR expression. Although only ∼20% of Vγ9Vδ2 T cells 
expressed CD56, more than 90% of NK cells were CD56bright, 
a characteristic of immature NK cells (Fig. 2 B). Overall, the 
surface phenotype of these NK cells is remarkably similar to 
that of NK cells isolated from the peripheral blood of IM 
patients (Azzi et al., 2014). A key difference is that those 
cells are CD56dim, a characteristic of mature NK cells. This 
difference in maturity is consistent with the NK cells in 
our 10-d cultures in vitro, with EBV having had a much 
shorter exposure to the virus than the 28–56 d that occurs 
in vivo before symptoms of IM manifest and diagnosis can 
be made (Hoagland, 1955).
In conclusion, the similarities between the phenotypes 
of NK cells and Vγ9Vδ2 T cells activated by EBV+ Akata cells 
raise the possibility that these cell populations make a comple-
mentary innate immune response to EBV in donors 2 and 3.
Bimodality and balance of the human 
Vγ9Vδ2 t cell response to EBV
That donors 2 and 3 made a Vγ9Vδ2 T cell response to Akata 
cells, whereas donor 1 did not (Fig. 1, A and B), points to a 
qualitative, bimodal variation in human immunity to EBV. We 
therefore extended the analysis to a cohort of 24 healthy do-
nors. Thirteen donors (group 1) made vigorous NK cell and 
Vγ9Vδ2 T cell responses to EBV, whereas 11 donors (group 2) 
made only the NK cell response (Fig. 3, A–C). The differen-
tial Vγ9Vδ2 T cell response of group 1 and 2 donors does not 
correlate with HLA type (Table S2), CMV status, prior expo-
sure to EBV, or sex. Three group 1 and two group 2 donors 
are CMV+; 12 group 1 and nine group 2 donors are EBV+; 
and five group 1 and four group 2 donors are females. No 
differences were detected in the NK cell responses of group 
1 and 2 donors to EBV, and no significant expansion of other 
invariant T cells, such as Vδ1 T cells, mucosal-associated in-
variant T cells (MAIT), or iNKT cells, was observed (Fig. S2).
To assess the role of IL2 in the NK cell and Vγ9Vδ2 T 
cell responses to Akata, PBMCs from group 1 donors were 
co-cultured in the presence or absence of IL2. In its presence, 
NK cells and Vγ9Vδ2 T cells proliferated, becoming >60% of 
the total cell number (Fig. 3 D). In the absence of IL2, lym-
phocyte activation was minimal, and Akata accounted for 60% 
of the proliferating cells (Fig.  3 D). To determine whether 
NK cell and Vγ9Vδ2 T cell responses to EBV depend on 
physical contact between PBMCs and Akata, cultures were 
made in a Transwell system that prevents such contact but 
supplies the cells with IL2. Under these conditions, neither 
NK cells nor Vγ9Vδ2 T cells proliferated (Fig. 3 D). Although 
the proportion of αβ T cells in these cultures increased, their 
absolute number did not (not depicted). These results demon-
strate how both IL2 and physical contact between lympho-
cytes and EBV-infected target cells are necessary to initiate 
the activation of NK cells and Vγ9Vδ2 T cells and their pro-
liferation in response to EBV.
We also examined whether autologous CD4 and CD8 
T cells are necessary for the activation of NK cells and 
Vγ9Vδ2 T cells. To do this, PBMCs from group 1 and group 
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Figure 2. EBV-stimulated nK cells and Vγ9Vδ2 t cells exhibit similar phenotypes of early differentiation. (A) Representative 3D plots showing 
the expression pattern of NKG2A, NKG2C, and KIR2DL3 by NK cells. NKG2A expression is given on the y axis, NKG2C expression on the x axis, and KIR2DL/3 
expression by the color of the data points, as depicted under signal intensity. Analyzed are the day 0 and 10 cultures of PBMCs, from CMV− (donor 1) and 
CMV+ (donor 3) individuals, that were stimulated with Akata and IL2. Shown are the results from one experiment, representing three performed. (B) Repre-
sentative viSNE maps of NK and Vγ9Vδ2 T cells at day 0 and NK cells and Vγ9Vδ2 T cells that proliferated during a 10-d stimulation of PBMCs with Akata 
cells and IL2. Each point in the viSNE map represents one cell; the points are colored to reflect the expression level of the indicated protein. Shown are the 
results from one experiment, representing three performed.
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Figure 3. Bimodality in the human Vγ9Vδ2 t cell response to EBV. (A) 2D plots showing the size of the Vγ9Vδ2 T cell subpopulation in total unstim-
ulated PBMCs and PBMCs after 10 d of culture with Akata cells. Representative data are shown for one group 1 donor (left; n = 13) and one group 2 donor 
(right; n = 11). (B) Pie charts showing the relative numbers (percentage of total cells) of Vγ9Vδ2 T cells, αβ T cells, NK cells, monocytes, B cells, and other 
cells in unstimulated PBMCs (day 0) and in PBMCs stimulated for 10 d with Akata cells (day 10). Mean values and SDs are given. For day 0 and day 10, the 
data for the group 1 donors (left; n = 13) and group 2 donors (right; n = 11) were analyzed separately. Statistically significant difference (P < 0.0001) was 
assessed between group 1 and group 2 Vγ9Vδ2 T cell proportions using ANO VA. (C) Histogram showing the absolute numbers of cells from cultures at day 
10 for all leukocytes, NK cells, and Vγ9Vδ2 T cells. Mean values and SDs are given. The data for the group 1 donors (n = 13) and group 2 donors (n = 11) 
were analyzed separately. Statistically significant difference (P < 0.0001) was assessed between group 1 and group 2 Vγ9Vδ2 T cell numbers using ANO VA. 
(D) Histogram showing the proportions of Vγ9Vδ2 T cells, αβ T cells, NK cells, and Akata cells after 10-d culture of PBMCs with Akata cells. Three conditions 
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2 donors were depleted of CD4 and CD8 T cells and then 
co-cultured with Akata cells. The response of group 1 do-
nors was dominated by Vγ9Vδ2 T cells, which accounted for 
∼70% of the cells and exceeded 50 million in number. NK 
cells accounted for ∼20% of the day 10 cells in the cultures 
(Fig. 3 E). In contrast, the response of group 2 donors was 
dominated by NK cells, accounting for >45 million cells and 
>60% of the total cell number. Vγ9Vδ2 T cells accounted for 
∼25% of the day 10 cells in the cultures of group 2 (Fig. 3 F). 
These results show that CD4 and CD8 T cells are not physi-
cally required for the NK cell and Vγ9Vδ2 T cell responses to 
EBV. This suggests that some EBV-induced antigens on the 
EBV-infected Akata cells are being directly recognized by the 
NK cells and Vγ9Vδ2 T cells.
Our results demonstrate how healthy humans divide 
into two groups whose Vγ9Vδ2 T cells respond in different 
ways to EBV. Group 1 makes a strong Vγ9Vδ2 T cell response 
to EBV, whereas group 2 makes a weak Vγ9Vδ2 T cell re-
sponse. A striking result is that the study cohort comprises al-
most equal numbers of group 1 and group 2 donors. This even 
balance suggests there has been a selective advantage to main-
taining both functional phenotypes in human populations.
Vγ9Vδ2 t cells from group 1 donors proliferate in response 
to type I EBV infection
Vγ9Vδ2 T cells have been shown to respond to Daudi, an 
EBV+ BL cell line (Sturm et al., 1990). Because Daudi, like 
Akata, maintains a latency I type of EBV infection, we hy-
pothesized that Vγ9Vδ2 T cells from group 1 donors would 
respond to this particular form of EBV latency. To test this 
possibility, we stimulated PBMCs from group 1 and group 
2 donors with four different types of EBV-infected B cell 
lines: type I BL cell lines (Daudi, Akata, and Kem-I); the 
Wp-restricted BL cell line Sal that expresses only EBNA1, 
3A, 3B, 3C, and a truncated form of EBNA-LP; type III BL 
cell lines (Raji and Jijoye), which express all latent EBV pro-
teins; and a lymphoblastoid B cell line (LCL; type III). The 
EBV− erythroleukemic cell line K562 provided the negative 
control. As predicted, Vγ9Vδ2 T cells from group 1 donors 
proliferated strongly in response to Daudi, Akata, and Kem-I 
(P < 0.0001). Group 1 Vγ9Vδ2 T cells also proliferated in re-
sponse to Sal (P < 0.008) but did not respond to Raji, Jijoye, 
LCL, or K562 (Fig.  4 A). These results show that group 1 
Vγ9Vδ2 T cells respond strongly to type I EBV latency and 
also to Wp-restricted EBV latency, but to a lesser extent.
Vγ9Vδ2 T cells respond to pyrophosphate-containing 
compounds, collectively called phosphoantigens (pAgs; Chien 
et al., 2014). This raises the possibility that type I BL cells 
maintain high concentrations of endogenous pAgs, metabo-
lites of the mevalonate pathway, and that these stimulate the 
Vγ9Vδ2 T cells of group 1 donors. To test this hypothesis, 
we stimulated PBMCs from group 1 donors with Akata and 
Daudi cells that were either preincubated or not with mev-
astatin, an inhibitor of the mevalonate pathway. Consistent 
with our hypothesis, Daudi and Akata cells preincubated with 
mevastatin failed to stimulate Vγ9Vδ2 T cells (Fig. 4 B).
We also examined whether the Vγ9Vδ2 T cells of group 
2 donors are exhausted. To do this, we stimulated PBMCs 
from group 1 and group 2 donors with high concentrations 
of exogenous isopentenyl pyrophosphate (IPP). Although the 
Vγ9Vδ2 T cells from group 2 donors made a less effective 
response than those from group 1 donors (P < 0.01), their 
number had risen by ∼180-fold after 10 d in culture, ac-
counting for a mean frequency of 38% of all the cells in the 
culture (Fig. 4 C). This clearly shows that group 2 Vγ9Vδ2 T 
cells are not exhausted or anergic.
Our results demonstrate that group 1 Vγ9Vδ2 T cells 
recognize and proliferate in response to type I EBV infection, 
which is characterized by high concentrations of endogenous 
pAgs in the infected cells. Moreover, we show that group 2 
Vγ9Vδ2 T cells are not anergic and can respond to a strong 
stimulation with exogenous pAgs, although significantly less 
well than the Vγ9Vδ2 T cells of group 1 donors.
Activation of Vγ9Vδ2 t cells by type I EBV infection 
involves cd277 and nKG2d
In responding to EBV, the Akata-activated Vγ9Vδ2 T cells 
and NK cells increase their expression of a battery of activat-
ing receptors (Fig. 2 B). To assess the functional contribution 
of these various receptors, we examined the effect of specific 
antagonistic mAbs on Akata-mediated activation. Also exam-
ined was the effect of antibody specific for CD277 (also called 
BTN3A1), a member of the butyrophilin family and essential 
for pAg-mediated activation of Vγ9Vδ2 T cells (Harly et al., 
2012; Vavassori et al., 2013; Sandstrom et al., 2014). CD277 is 
expressed by both effector and target cells, but its expression 
by either NK cells or Vγ9Vδ2 T cells was not significantly 
altered upon exposure to type I EBV infection. Aliquots of 
PBMCs from group 1 donors were treated with antagonistic 
mAbs specific for five activating receptors and CD277 or with 
control mouse IgG and then cultured with Akata for 10 d. 
To also assess the effect of CD277 on target cells, we prein-
cubated Akata target cells with anti-CD277 or with control 
mouse IgG and then cultured them for 10 d with PBMCs.
Control IgG and antagonistic antibodies specific for 
NKp30, DNAM-1, 2B4, and CD2 had no effect on Akata- 
mediated activation and proliferation of Vγ9Vδ2 T cells. 
In contrast, anti-NKG2D significantly reduced the Akata- 
were used: presence of IL2, absence of IL2, and presence of IL2 with separation of PBMCs from Akata targets by a Transwell (TW) system. PBMCs from three 
group 2 donors were studied. Shown is one representative of three experiments performed. (E and F) Histograms showing the proportions and absolute 
numbers of NK cells and Vγ9Vδ2 T cells after 10-d culture of PBMCs, depleted of CD4 and CD8 T cells, with Akata cells and IL2. Mean values ± SD are given. 
PBMCs from three group 1 donors (E) and three group 2 donors (F) were studied.
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mediated proliferation (P = 0.003), which was completely 
abrogated by anti-CD277 (P < 0.0001). Vγ9Vδ2 T cell 
proliferation was also significantly reduced when Akata 
were preincubated with anti-CD277 (P < 0.0001). These 
results demonstrate the importance of the activation of 
NKG2D on Vγ9Vδ2 T cells and CD277 on both Vγ9Vδ2 T 
cells and Akata (Fig. 5).
Whereas anti-CD277 effectively blocked Vγ9Vδ2 T 
cell activation, this antibody increased the proportion of NK 
cells. The effect was observed if either Akata or PBMCs were 
preincubated with anti-CD277 (P = 0.01). As no significant 
increase in the absolute number of NK cells was observed, 
this result could be a direct consequence of the decrease in 
the relative number of Vγ9Vδ2 T cells in the cell cultures. 
Among the antagonistic mAbs against activating receptors, 
anti-NKp30 caused a slight inhibition of the NK cell response 
(P = 0.08), but mAbs specific for DNAM-1, 2B4, CD2, and 
NKG2D had no effect (Fig. 5).
In summary, our results demonstrate an essential role for 
CD277 and an important contribution from NKG2D in the 
Vγ9Vδ2 T cell response to type I EBV infection. These find-
ings are consistent with previous studies showing a critical co-
stimulatory role for CD277 (Harly et al., 2012; Vavassori et al., 
2013; Sandstrom et al., 2014) and NKG2D (Das et al., 2001; 
Nedellec et al., 2010) in Vγ9Vδ2 T cell activation by pAgs.
Group 1 Vγ9Vδ2 t cells are functionally more 
potent in their response to type I EBV infection 
than group 2 Vγ9Vδ2 t cells
We investigated whether Vγ9Vδ2 T cells from group 1 donors 
make stronger functional responses to type I EBV infection 
than Vγ9Vδ2 T cells from group 2 donors, as well as exhib-
iting more extensive proliferation. To do this, we stimulated 
PBMCs from group 1 and group 2 donors with Akata and 
Daudi cells in a 24-h culture. As negative controls, PBMCs 
were also cultured alone or with type III EBV-infected Raji 
cells. Cytotoxic activity of the Vγ9Vδ2 T cells was assessed 
by flow cytometry to measure the intracellular production 
of granzyme B (Fig. 6 A). With this approach, we similarly 
evaluated the capacity of Vγ9Vδ2 T cells to produce a major 
cytokine, IFNγ (Fig. 6 B), and a major chemokine, MIP1-β 
(Fig. 6 C), of γδ T cells.
Vγ9Vδ2 T cells from group 1 donors made stronger 
responses to Akata and Daudi than Vγ9Vδ2 T cells from 
group 2 donors, as assessed by granzyme B production (P < 
0.004 for Akata and P < 0.0001 for Daudi; Fig. 6 A). Similar 
Figure 4. Vγ9Vδ2 t cells from group 1 do-
nors proliferate in response to type I EBV 
infection. (A) PBMCs from six group 1 donors 
(orange) and six group 2 donors (green) were 
stimulated in culture for 10 d with IL2 and tar-
get cells. The targets were type I BL cell lines 
(Daudi, Akata, and Kem-I), the Wp-restricted 
BL cell line Sal, type III BL cell lines (Raji and 
Jijoye), and type III EBV-infected LCL and K562. 
Bar graphs give the proportion of Vγ9Vδ2 
T cells after the 10-d culture. Mean values ± 
SEM are also given. Statistically significant 
difference between each experimental target 
cell and the negative control, K562 cells, was 
assessed using ANO VA (**, P < 0.008; ***, P < 
0.0001). (B) PBMCs from six group 1 donors 
were stimulated in culture for 10 d with IL2 
and target cells. The targets were Daudi and 
Akata, either preincubated (light pink) or not 
preincubated (orange) for 24  h with 80  µM 
mevastatin (Mev). Boxes and whiskers rep-
resent the proportion of Vγ9Vδ2 T cells after 
the 10-d culture. Statistical significance in the 
difference between experiment and control 
was assessed using ANO VA (***, P < 0.0001). 
(C) Boxes and whiskers represent the propor-
tion of Vγ9Vδ2 T cells after 10-d culture of 
PBMCs from eight group 1 donors (orange) and 
eight group 2 donors (green), in the presence 
of 100 µM IPP and IL2. Statistical significance 
in the difference between the two groups was 
assessed using the unpaired two-tailed Stu-
dent’s t test (**, P < 0.01).
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differences between group 1 and group 2 donors were ob-
served for IFNγ production (P < 0.0006 for Akata and P < 
0.0001 for Daudi; Fig. 6 B) as well as for MIP1-β production 
(P < 0.0001 for both Akata and Daudi; Fig. 6 C). The results 
from these three functional assays demonstrate that Vγ9Vδ2 
T cells from group 1 donors exhibit a more effective im-
mune response to type I EBV infection than the Vγ9Vδ2 T 
cells from group 2 donors (Fig.  6). In conclusion, Vγ9Vδ2 
T cells from group 1 donors have greater capacity for both 
proliferation and effector response than the corresponding 
cells from group 2 donors.
Bimodality in the human Vγ9Vδ2 t cell 
response to EBV in vivo
During acute IM, infected memory B cells accumulate in the 
blood and exhibit a phenotype similar to BL with type I EBV 
infection (Hochberg et al., 2004). We therefore investigated 
whether the dichotomous Vγ9Vδ2 T cell response to EBV 
observed in vitro also occurs in vivo. We assessed frequen-
cies and total cell numbers of NK cells, CD4 T cells, CD8 
T cells, B cells, iNKT cells, Vδ1 T cells, and Vγ9Vδ2 T cells 
in the peripheral blood of 17 healthy children and 17 chil-
dren experiencing acute IM. Consistent with previous ob-
servations (Williams et al., 2005; Hislop et al., 2007; Azzi et 
al., 2014), we found that the blood of children with acute 
IM had high numbers of NK cells (P = 0.0005) and CD8 T 
cells (P < 0.0001). To lesser extent, the CD4 T cell numbers 
were also increased in the IM patients (P = 0.04). No signif-
icant changes in B cell number were observed in children 
with acute IM (Fig. 7 A). Overall, iNKT cell numbers were 
increased in children with IM (P < 0.0001), but there were 
no differences between patients and controls in the numbers 
of γδ T cells bearing Vδ1 TCR chains (Fig.  7 B). In con-
trast, high numbers of Vγ9Vδ2 T cells, exceeding 5% of total 
lymphocytes, were seen in four IM patients and six healthy 
EBV+ controls. The absolute numbers of Vγ9Vδ2 T cells were 
similarly increased in these individuals (Fig. 7, B and C). Fur-
thermore, there was no correlation between the proportions 
of Vγ9Vδ2 T cells and NK cells in children with acute IM. 
It is important to note that IM patients have higher num-
bers of PBMCs than controls because of their acute infection 
and the inflammation it causes. Consequently, the number 
of IM patients having a high absolute number of Vγ9Vδ2 T 
cells is even greater than that of the four bona fide group 
1 patients (Fig. 7 B).
We found that the cohorts of healthy EBV+ children 
and acute IM patients both include group 1 individuals with 
high number and proportion of Vγ9Vδ2 T cells and group 2 
individuals with low number and proportion of Vγ9Vδ2 T 
cells. The cohort of healthy EBV+ children included a larger 
number of group 1 individuals (46%; n = 6) than the co-
hort of acute IM patients (23.5%; n = 4). The EBV+ healthy 
children, all 10 years old or younger (Fig. 7 D), were likely 
to have been infected with EBV without subsequent devel-
opment of IM. Consistent with this interpretation, the group 
1 IM patients followed longitudinally maintained high fre-
quencies of Vγ9Vδ2 T cells 6 mo after diagnosis of acute IM 
and clearance of EBV-related symptoms (Fig.  7 C). More-
over, such high Vγ9Vδ2 T cell frequencies were not ob-
served among EBV+ healthy adults who fully controlled EBV 
and for whom Vγ9Vδ2 T cells never exceeded 5% of total 
lymphocytes (Fig. 7 C).
dIscussIon
In making an innate immune response to EBV, human indi-
viduals form two distinctive groups that differ according to 
the types of lymphocytes recruited to the response. Group 
1 individuals make both an NK cell and a Vγ9Vδ2 T cell re-
Figure 5. A role for cd277 and nKG2d in 
the activation of Vγ9Vδ2 t cells by type 
I EBV infection. PBMCs from eight group 1 
donors were preincubated with antagonis-
tic mAbs against NKp30, DNAM-1, 2B4, CD2, 
NKG2D, CD277, or a control mouse IgG. They 
were then stimulated with Akata for 10 d in 
the presence of IL2. In other cultures, PBMCs 
alone were stimulated for 10 d with Akata cells 
preincubated with anti-CD277 or IgG control. 
Boxes and whiskers represent the proportion 
of Vγ9Vδ2 T cells (orange) and NK cells (yel-
low) after the 10-d culture with Akata cells. 
Hatched boxes and whiskers represent the 
proportion of Vγ9Vδ2 T cells (orange) and NK 
cells (yellow) after the 10-d culture with Akata 
cells preincubated with anti-CD277 or IgG 
control. Statistical significance of the differ-
ence between experiment and control was as-
sessed using ANO VA (*, P = 0.01; **, P < 0.003; 
***, P < 0.0001; ns, nonsignificant).
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sponse. In contrast, group 2 individuals make only an NK cell 
response, but it is a stronger one than that made by group 
1 individuals. Of the 24 blood donors we studied, 13 are in 
group 1 and 11 are in group 2, indicating that the human 
population divides evenly into these two groups. In the con-
text of the human immune response to EBV, there is bimo-
dality in the Vγ9Vδ2 T cell response, in which around half the 
population is responsive and the other half is not. At the level 
of the species and its constituent populations, the balance of 
these two functional phenotypes argues for both of them hav-
ing functional benefit and selective advantage.
The qualitative difference in the γδ T cell response 
of group 1 and group 2 individuals does not correlate with 
sex. Neither is it caused by a deficiency of Vγ9Vδ2 T cells 
in the group 2 donors, because in all individuals Vγ9Vδ2 
T cells represent ∼0.5–1.5% of the PBMCs. Nor does the 
difference correlate with prior exposure to EBV, because 
a large majority of the donors we studied (21 of 24) were 
EBV infected. Thus, some other mechanism must underlie 
this intriguing difference in the innate immune response to 
EBV. To our knowledge, no differential human γδ T cell im-
mune response to EBV, or any other infection or cancer, has 
been previously described.
Vγ9Vδ2 T cells, which represent only 1–4% of peripheral 
blood T cells in healthy adults, are increased in number in 
patients infected with Mycobacterium tuberculosis and other 
pathogens. This proliferation occurs when the Vγ9Vδ2 T cells 
recognize microbial pAgs (Chen, 2013). Here, we show that 
Vγ9Vδ2 T cells from group 1 donors are strongly activated 
by type I EBV infection, which is characterized by high 
concentrations of endogenous pAgs in the infected cells. 
That the Daudi cell line elicits a more vigorous stimulation of 
Vγ9Vδ2 T cells than other type I BL cell lines is probably a 
result of its lack of β2-microglobulin, which causes complete 
down-regulation of cell-surface HLA class I (Nilsson et al., 
1974). Consequently, the Vγ9Vδ2 T cells, which lack inhibitory 
KIR but express high surface levels of CD94 :NKG2A, are not 
inhibited through the interaction of this inhibitory receptor 
with its HLA-E ligand. We also demonstrate that group 2 
Vγ9Vδ2 T cells are not anergic. They do respond to a strong 
stimulation with exogenous pAgs, although to lesser extent 
than the Vγ9Vδ2 T cells of group 1 donors.
Consistent with these in vitro data is our study and 
comparison of cohorts of healthy EBV+ children and pediat-
ric IM patients. Both cohorts included a balance of group 1 
individuals with high numbers of peripheral blood Vγ9Vδ2 
T cells, and group 2 individuals, with low numbers. Given 
their very young age, the group 1 EBV+ healthy children are 
likely to carry an asymptomatic EBV infection. Although the 
size of these cohorts is small, that the cohort of EBV+ healthy 
children included a larger number of group 1 individuals sug-
gests that Vγ9Vδ2 T cells play a beneficial role in the innate 
immune response to EBV.
In a previous study, Vγ9Vδ2 T cell clones cultured from 
the PBMCs of a kidney transplant recipient all made a ro-
Figure 6. Group 1 Vγ9Vδ2 t cells are functionally more potent 
in their response to type I EBV infection than group 2 Vγ9Vδ2 t 
cells. PBMCs from six group 1 donors and six group 2 donors were in-
cubated in culture either alone (Ø) or in the presence of target cells. The 
targets were Raji (a negative control), Akata, and Daudi. (A) Boxes and 
whiskers represent the proportion of granzyme B+ Vγ9Vδ2 T cells from 
group 1 donors (orange) and group 2 donors (green) after 24-h culture. 
(B) Boxes and whiskers represent the proportion of IFNγ+ Vγ9Vδ2 T cells 
from group 1 donors (orange) and group 2 donors (green) after 24-h cul-
ture. (C) Boxes and whiskers represent the proportion of MIP1-β+ Vγ9Vδ2 
T cells from group 1 donors (orange) and group 2 donors (green) after 
24-h culture. Statistical significance of the difference between experi-
ment and control was assessed using ANO VA (*, P ≤ 0.04; **, P < 0.004; 
***, P ≤ 0.0006; ns, nonsignificant).
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bust response to Daudi cells. In contrast, only a few of the 
Vγ9Vδ2 T clones cultured from human fetal tissue responded 
to Daudi. To explain this difference, the authors proposed a 
mechanism of γδ T cell selection by pAgs, which acts after 
birth in peripheral tissues to increase the representation of 
Daudi-reactive Vγ9Vδ2 T cells (Davodeau et al., 1993). In 
the context of this model, group 2 donors could have fewer 
Vγ9Vδ2 TCRs that recognize the pAgs presented by type I 
EBV-infected B cells. Consequently, characterization of the 
structure and diversity of the γδ TCRs of Vγ9Vδ2 T cells 
stimulated by type I EBV infection could be an important 
next step toward understanding why approximately half the 
human population cannot make a Vγ9Vδ2 T cell response. 
We find that CD277 and NKG2D play essential roles in the 
Vγ9Vδ2 T cell response to type I EBV infection, suggesting 
that polymorphism in the CD277 and NKG2D genes could 
be genetic factors that contribute to the differential response 
to EBV of group 1 and group 2 donors. Further investiga-
tion will be needed to determine the contributions made by 
CD277 on target cells and effector cells in the Vγ9Vδ2 T cell 
response to type I EBV infection.
That NK cells have a beneficial role in the human in-
nate immune response to EBV infection is a concept now 
generally accepted (Williams et al., 2005; Pappworth et al., 
2007; Chijioke et al., 2013; Azzi et al., 2014). In previous in-
vestigations, NK cells were seen to be more effective killers 
of B cells with lytic EBV infection than B cells with latent 
EBV infection (Pappworth et al., 2007; Williams et al., 2016). 
In contrast, we find that Akata cells with lytic infection in-
duce less NK cell proliferation than Akata cells with latent 
infection. During early phases of lytic infection, Akata both 
down-regulates HLA class I expression and up-regulates ex-
pression of the ligands for activating NK cell receptors. This 
intriguing difference between effector function and prolif-
eration could be caused by a hierarchy of signaling path-
ways, which allows cytolysis to be induced in the absence 
Figure 7. Bimodality in the human Vγ9Vδ2 t cell response to EBV in vivo. (A) Scatter plots represent the absolute numbers of NK cells (yellow), 
CD8 T cells (light violet), CD4 T cells (dark violet), and B cells (green) in peripheral blood of children experiencing acute IM (circles) and healthy children 
(triangles). EBV− healthy children are indicated by black triangles. Mean values are given. Statistical significance in the difference between IM and healthy 
children was assessed using the unpaired Student’s t test (*, P = 0.04; ***, P ≤ 0.0005; ns, nonsignificant). (B) Scatter plots represent the absolute numbers 
of iNKT cells (dark blue), Vδ1 T cells (light blue), and Vγ9Vδ2 T cells (orange) in peripheral blood of children experiencing acute IM (circles) and healthy 
children (triangles). EBV− healthy children are indicated by black triangles. Statistical significance in the difference between IM and healthy children was 
assessed using the unpaired Student’s t test (***, P < 0.0001; ns, nonsignificant). (C) Scatter plots represent the proportion of Vγ9Vδ2 T cells in peripheral 
blood of children experiencing acute IM (circles), children at 6 mo after the diagnosis of IM (crossed circles), healthy children (triangles), and healthy adults 
(diamonds). EBV− healthy children are indicated by black triangles. (D) Scatter plots represent the age of children experiencing acute IM (circles) and healthy 
children (triangles). Children who exhibited high proportions of Vγ9Vδ2 T cells are indicated in orange.
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of NK-cell division. Consistent with this mechanism, our 
experiments to stimulate PBMCs with HLA-deficient K562 
cells, an iconic NK cell target, induced a low proliferation of 
NK cells (unpublished data).
NK cells responding to Akata increase their surface 
expression of activating receptors and exhibit the characteristic 
CD56brightCD94 :NKG2AhighKIR− phenotype of early NK 
cell differentiation. These results complement and extend 
previous studies of an increased number of immature NK 
cells in the blood of IM patients (Williams et al., 2005; Azzi 
et al., 2014). The phenotype of the Akata-stimulated Vγ9Vδ2 
T cells is remarkably similar to that of the Akata-stimulated 
NK cells. This suggests that both NK cells and Vγ9Vδ2 T 
cells recognize EBV-induced costimulatory ligands, possibly 
activating NK cell receptor and γδ T cell receptor ligands, 
which drive their selection and proliferation.
Unexpectedly, our study uncovered a phenotypic di-
morphism in the human innate immune response to EBV. 
Approximately one-half of the population responds to EBV 
with NK cells and Vγ9Vδ2 T cells, whereas the other half 
responds with NK cells alone. Increasing evidence points to 
the contribution of γδ T cells to innate immunity against viral 
infection. In vitro pAg-stimulated Vγ9Vδ2 T cells can prevent 
EBV-induced malignancy in humanized mice (Xiang et al., 
2014). After birth, age-related increases in the number and 
frequency of human peripheral blood Vγ9Vδ2 T cells (Parker 
et al., 1990) might explain why primary EBV infection in 
very early childhood is usually asymptomatic. The striking 
difference we see in the human innate immune response 
to EBV in vitro could explain both the clinical course and 
outcome of primary EBV infections, as well as the suscepti-
bility of immunocompromised individuals to EBV-induced 
malignancy. Because Vγ9Vδ2 T cells are known to respond 
to other herpesviruses, notably herpes simplex virus (Bukow-
ski et al., 1994) and CMV (Daguzan et al., 2016), a crucial 
and intriguing question is whether the bimodality of the 
human innate immune response is specific to EBV or pertains 
to other herpesviruses.
MAtErIALs And MEtHods
cells and cell culture
Blood samples were collected from healthy adult volun-
teer donors and purchased as anonymized LRS chambers 
from the Stanford Blood Center. PBMCs were isolated by 
density gradient centrifugation (Ficoll-Paque PLUS; GE 
Healthcare) as recommended by the manufacturer and 
cryopreserved in FBS (Gemini) supplemented with 10% 
DMSO (EMD Millipore).
Samples from 17 pediatric patients diagnosed with acute 
IM and 17 healthy children undergoing elective tonsillec-
tomy at the University Children’s Hospital of Zurich were 
collected as described (Azzi et al., 2014). All participants pro-
vided informed consent in accordance with the Declaration 
of Helsinki, and the institutional ethics committee approved 
all protocols used (KEK-ZH Nr. St 40/05).
Cryopreserved PBMCs were thawed, suspended in 
RPMI 1640 medium (Corning Cellgro), and centrifuged 
for 5 min at 1,500 rpm. Cell pellets were resuspended in 
RPMI 1640 containing 10% heat-inactivated FBS and kept 
at 37°C overnight. This period of culture allowed the PBMCs 
to recover from the freeze-thaw before subjecting them to 
in vitro experimentation.
The EBV+ and EBV− Akata cell lines were provided 
by J. Sample (Pennsylvania State University, State College, 
PA). EBV+ Akata maintains a type I EBV infection and can 
be induced to enter the EBV lytic cycle by cross-linking 
of its BCR. Akata (Takada et al., 1991), Daudi (Klein et al., 
1968), and Kem-I (Gregory et al., 1990) are type I BL cell 
lines. Sal is a Wp-restricted BL cell line (Kelly et al., 2002). 
Kem-I and Sal were provided by S. Kenney (University of 
Wisconsin-Madison, Madison, WI). LCLs were generated by 
infecting freshly isolated PBMCs with the B95.8 strain of 
EBV as described (Neitzel, 1986). Raji (Pulvertaft, 1964) 
and Jijoye (Kohn et al., 1967) are type III BL cell lines, 
which were purchased from ATCC. K562 is an EBV− HLA 
class I–deficient erythroleukemia cell line. All cell lines were 
cultured in RPMI 1640 containing heat-inactivated FBS 
(10%), l-glutamine (5  mM), and streptomycin/penicillin 
(100 IU/100 µg/ml; Thermo Fisher Scientific). All cell lines 
were confirmed to be EBV− or EBV+, using a PCR-based 
assay that tests for the presence of DNA encoding EBNA1 
(Yap et al., 2007). All cell cultures were performed at 37°C, 
unless stated otherwise.
Induction of the EBV lytic cycle in Akata cells
Akata cells (107) were incubated with polyclonal goat anti–
human F(ab) IgG (1%; Thermo Fisher Scientific) for 3 h at 
37°C. To remove unbound antibody, the cells were diluted in 
RPMI 1640, centrifuged for 5 min at 1,500 rpm, and sub-
sequently resuspended at 106 cells/ml in fresh RPMI 1640 
containing 10% heat-inactivated FBS.
Assay of cellular proliferation in response to EBV
Five million PBMCs were cultured with target cells at an 
effector-to-target cell ratio of 10:1, in a 24-well plate. Cells 
were cultured in RPMI 1640 containing heat-inactivated FBS 
(5%), heat-inactivated human AB serum (5%; Sigma Aldrich), 
l-glutamine (2  mM), streptomycin/penicillin (100 IU/100 
µg/ml), and recombinant human IL2 (200 IU/ml). The IL2 
was obtained from M. Gately (Hoffmann-La Roche) through 
the AIDS Reagent Program, Division of AIDS, National In-
stitute of Allergy and Infectious Diseases, National Institutes 
of Health, Bethesda, MD. Cells were passaged upon reaching 
confluence and were supplemented with fresh medium every 
2 d for a period of 10 d. Transwell experiments, which in-
vestigated the need for direct contact between effector cells 
and target cells, were performed in 24-well plates. The Akata 
target cells were placed in Transwell inserts (0.4 µM; Corning) 
and PBMCs, the source of effector cells, were cultured in the 
wells beneath the inserts.
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In some experiments, Akata and Daudi cells were pre-
incubated for 24 h with 80 µM mevastatin (Sigma-Aldrich). 
For stimulations with 100 µM exogenous IPP (Santa Cruz 
Biotechnology, Inc.), 200,000 PBMCs per well were cultured 
in 96-well plates and passaged upon reaching confluence. In 
blocking experiments, PBMCs were incubated for 30 min at 
4°C with a control IgG or a blocking mAb at a concentra-
tion of 10 µg/ml, before the addition of target cells. Blocking 
antibodies were specific for NKp30 (210845; R&D Sys-
tems), DNAM-1 (DX11; BD Biosciences), 2B4 (eBioPP35; 
eBioscience), CD2 (RPA-2.10; BioLegend), NKG2D 
(149810; R&D Systems), and CD277 (103.2; Compte et al., 
2004). In some experiments, anti-CD277 was used to block 
CD277 on Akata cell targets.
Functional assays
500,000 PBMCs were cultured alone or in the presence of 
Akata, Daudi, or Raji (negative control) cells at an effector 
to target cell ratio of 10:1. Cells were cultured for 24 h in a 
96-well plate in RPMI 1640 containing heat-inactivated FBS 
(5%), heat-inactivated human AB serum (5%), l-glutamine 
(2  mM), streptomycin/penicillin (100 IU/100 µg/ml), and 
recombinant human IL2 (200 IU/ml). Brefeldin A (BD) was 
added to the cultures for the last 4 h. Cells were then stained 
for flow cytometry analysis, which measured the frequency of 
Vγ9Vδ2 T cells expressing granzyme B+, IFNγ+, and MIP1-β+.
Antibodies and analysis by flow cytometry
Anti-BZLF1 (BZ1), conjugated to AF488 (Thermo 
Fisher Scientific), was provided by M. Rowe (Young et al., 
1991). This antibody was used to assess EBV reactivation 
after BCR cross-linking.
Cells proliferating after 10 d of culture with EBV+ or 
EBV− Akata cells and unstimulated control cells were as-
sessed by flow cytometry using the following five mouse 
mAb conjugates (BioLegend): anti-CD3 (UCHT1-PerCP), 
anti-CD56 (HCD56-PE), anti-TCRVδ2 (B6-FITC), anti- 
CD14 (HCD14-PE), and anti-CD20 (2H7-APC). For func-
tional assays, PBMCs were stained using anti-CD3 (UCHT1-
PerCP) and anti-TCRVδ2 (B6-FITC). Cells were then fixed 
and permeabilized using Fixation/Permeabilization Solution 
kit (BD) as recommended by the manufacturer. Vγ9Vδ2 T 
cell function was assessed using mAbs specific for granzyme 
B (GB11-Alexa Fluor 647; BioLegend), IFNγ (Β27−ΠΕ; 
BioLegend), and MIP1-β (D21-1351-PE; BD). Data were 
collected with an Accuri C6 instrument (BD) and analyzed 
using FlowJo software version 10.1.
B cell purification and detection of EBV genomic dnA
B cells were purified from the PBMCs of healthy volunteer 
donors using the Dynabeads Isolation kit (Thermo Fisher 
Scientific) as recommended by the manufacturer. Genomic 
DNA was isolated from peripheral blood B cells and cell lines 
using the QIAamp DNA Blood Mini kit (QIA GEN). A region 
of the EBNA1 gene was amplified by PCR (forward primer: 
5′-GGT AGA AGG CCA TTT TTC CAC-3′; reverse primer: 
5′-CTC CAT CGT CAA AGC TGC AC-3′) as described (Yap 
et al., 2007).
conjugation of antibodies for use in mass cytometry
A panel of 31 antibodies was used for the analysis of cells by 
mass cytometry (Table S1). Metal-ion conjugates of these an-
tibodies were prepared using the Maxpar Antibody Labeling 
kit (Fluidigm) as recommended by the manufacturer. Conju-
gated antibodies were diluted in a proprietary “PBS Antibody 
Stabilization solution” (Candor Bioscience GmbH) to con-
centrations between 0.1 and 0.3 mg/ml and stored at 4°C. 
Each metal-conjugated antibody was titrated to give optimal 
staining of PBMCs. Staining was performed on cryopreserved 
cells that had been thawed, washed and allowed to recover by 
overnight culture at 37°C.
Mass cytometry: staining, data collection, and data analysis
Unstimulated PBMCs and cells proliferating after 10 d of cul-
ture were stained with a panel of 31 mAbs (Table S1) as de-
scribed (Newell et al., 2012; Horowitz et al., 2013). Cells were 
also stained with Cell-ID Intercalator-Ir (Ir191 and Ir193) 
and Cell-ID Cisplatin (Pt195) to assess DNA content and cell 
viability. Mass cytometry data were obtained with a CyTOF 
2 instrument (Fluidigm) in the Stanford Shared FACS Facility. 
The data were analyzed using Cytobank software.
depletion of cd4 and cd8 t cells from PBMcs
Depletion of CD4 and CD8 T cells from PBMCs was achieved 
by using the Dynabeads Isolation kit (Thermo Fisher Scien-
tific) as recommended by the manufacturer.
HLA genotyping and cMV serology
HLA-A, -B, and -C genotypes for blood donors were de-
termined by PCR-based sequence-specific oligonucleotide 
probes, using a Luminex 100 instrument (Luminex Corp.). 
The assays were performed with LABType SSO reagents 
(One Lambda). HLA-A, -B, and -C genotypes for Akata were 
determined using next generation sequencing–based meth-
odology, as previously described (Norman et al., 2016). The 
CMV status of the donors was determined serologically at 
the Stanford Blood Center.
statistical analyses
Data were analyzed using Prism software. P-values were cal-
culated using one-way ANO VA or unpaired Student’s t test, 
as appropriate. P-values of <0.05 were considered significant.
online supplemental material
Fig. S1 shows the sequential gating strategy to identify NK 
and Vγ9Vδ2 T cells from unstimulated PBMCs. Fig. S2 shows 
that Vδ1 T cells, MAIT cells, and iNKT cells do not signifi-
cantly respond to EBV infection. Table S1 shows a mass cy-
tometry antibody panel. Table S2 shows HLA-A, -B, and -C 
genotypes of donors 4–24.
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